389 related articles for article (PubMed ID: 25901081)
1. CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer.
Svensson S; Abrahamsson A; Rodriguez GV; Olsson AK; Jensen L; Cao Y; Dabrosin C
Clin Cancer Res; 2015 Aug; 21(16):3794-805. PubMed ID: 25901081
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER
Abrahamsson A; Rodriguez GV; Dabrosin C
Cancer Res; 2020 Oct; 80(20):4487-4499. PubMed ID: 32855207
[TBL] [Abstract][Full Text] [Related]
3. The inflammatory chemokines CCL2 and CCL5 in breast cancer.
Soria G; Ben-Baruch A
Cancer Lett; 2008 Aug; 267(2):271-85. PubMed ID: 18439751
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
[TBL] [Abstract][Full Text] [Related]
5. CCL2 conditionally determines CCL22-dependent Th2-accumulation during TGF-β-induced breast cancer progression.
Mandal PK; Biswas S; Mandal G; Purohit S; Gupta A; Majumdar Giri A; Roy Chowdhury S; Bhattacharyya A
Immunobiology; 2018 Feb; 223(2):151-161. PubMed ID: 29107385
[TBL] [Abstract][Full Text] [Related]
6. Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy.
Nie Y; Huang H; Guo M; Chen J; Wu W; Li W; Xu X; Lin X; Fu W; Yao Y; Zheng F; Luo ML; Saw PE; Yao H; Song E; Hu H
Clin Cancer Res; 2019 Jul; 25(13):3873-3886. PubMed ID: 30890553
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer.
Lindahl G; Saarinen N; Abrahamsson A; Dabrosin C
Cancer Res; 2011 Jan; 71(1):51-60. PubMed ID: 21097717
[TBL] [Abstract][Full Text] [Related]
8. Innate signaling mechanisms controlling Mycobacterium chelonae-mediated CCL2 and CCL5 expression in macrophages.
Kim YS; Kim JH; Woo M; Kim TS; Sohn KM; Lee YH; Jo EK; Yuk JM
J Microbiol; 2015 Dec; 53(12):864-74. PubMed ID: 26626357
[TBL] [Abstract][Full Text] [Related]
9. RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration.
Datar I; Qiu X; Ma HZ; Yeung M; Aras S; de la Serna I; Al-Mulla F; Thiery JP; Trumbly R; Fan X; Cui H; Yeung KC
Oncotarget; 2015 Nov; 6(36):39050-61. PubMed ID: 26375811
[TBL] [Abstract][Full Text] [Related]
10. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling.
Han R; Gu S; Zhang Y; Luo A; Jing X; Zhao L; Zhao X; Zhang L
Sci Rep; 2018 Jun; 8(1):9575. PubMed ID: 29934505
[TBL] [Abstract][Full Text] [Related]
11. IL-6 Mediates Macrophage Infiltration after Irradiation via Up-regulation of CCL2/CCL5 in Non-small Cell Lung Cancer.
Wang X; Yang X; Tsai Y; Yang L; Chuang KH; Keng PC; Lee SO; Chen Y
Radiat Res; 2017 Jan; 187(1):50-59. PubMed ID: 28054838
[TBL] [Abstract][Full Text] [Related]
12. Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88.
Egunsola AT; Zawislak CL; Akuffo AA; Chalmers SA; Ewer JC; Vail CM; Lombardo JC; Perez DN; Kurt RA
Cell Immunol; 2012; 272(2):220-9. PubMed ID: 22088941
[TBL] [Abstract][Full Text] [Related]
13. Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils.
Vazquez Rodriguez G; Abrahamsson A; Jensen LD; Dabrosin C
Cancer Immunol Res; 2017 Mar; 5(3):234-247. PubMed ID: 28159748
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of chemokine expression by estrogen in human periodontal ligament cells.
Nebel D; Jönsson D; Norderyd O; Bratthall G; Nilsson BO
J Periodontal Res; 2010 Dec; 45(6):796-802. PubMed ID: 20701669
[TBL] [Abstract][Full Text] [Related]
15. Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells.
Haberstroh U; Pocock J; Gómez-Guerrero C; Helmchen U; Hamann A; Gutierrez-Ramos JC; Stahl RA; Thaiss F
Kidney Int; 2002 Oct; 62(4):1264-76. PubMed ID: 12234296
[TBL] [Abstract][Full Text] [Related]
16. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
[TBL] [Abstract][Full Text] [Related]
17. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.
Zhang Y; McCormick LL; Desai SR; Wu C; Gilliam AC
J Immunol; 2002 Mar; 168(6):3088-98. PubMed ID: 11884483
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer.
Zeng H; Hou Y; Zhou X; Lang L; Luo H; Sun Y; Wan X; Yuan T; Wang R; Liu Y; Tang R; Cheng S; Xu M; Liu M
Theranostics; 2022; 12(17):7351-7370. PubMed ID: 36438499
[No Abstract] [Full Text] [Related]
19. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.
Li Z; Carrier L; Belame A; Thiyagarajah A; Salvo VA; Burow ME; Rowan BG
Breast Cancer Res Treat; 2009 Nov; 118(1):33-43. PubMed ID: 18855134
[TBL] [Abstract][Full Text] [Related]
20. CCR2 Chemokine Receptors Enhance Growth and Cell-Cycle Progression of Breast Cancer Cells through SRC and PKC Activation.
Yao M; Fang W; Smart C; Hu Q; Huang S; Alvarez N; Fields P; Cheng N
Mol Cancer Res; 2019 Feb; 17(2):604-617. PubMed ID: 30446625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
